Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Change Puts Hatch, Gregg, Grassley In Line For Key Rx Committees

Executive Summary

The transfer of control in the Senate puts Sen. Orrin Hatch (R-Utah) in position to have greater influence in guiding generic drug reform legislation
Advertisement

Related Content

Medicare Rx “Tripartisan” Group Backing Away From $400 Bil. Cost
Medicare Rx “Tripartisan” Group Backing Away From $400 Bil. Cost
GPhA Adds Legislative Staffer For Republican Focus, Creates PAC
GPhA Adds Legislative Staffer For Republican Focus, Creates PAC
Senate GOP Victories Leave Frist As First Among Equals On Health Issues
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
FDA Labeling Standards Top Kennedy’s Agenda For Commissioner Nominee
FDA, USP Should Set Generic Biologics Standards, Sen. Hatch Proposes
Senate “Tripartisan” Medicare Rx Drug Bill To Have 50% Copay, $35 Premium
Advertisement
UsernamePublicRestriction

Register

PS040781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel